HUNAN JIUDIAN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.52 CNY | -1.91% |
|
-1.50% | +12.91% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 6,289 | 8,247 | 8,333 | 11,469 | 12,950 | - | - |
| Enterprise Value (EV) 1 | 6,289 | 8,247 | 8,333 | 11,469 | 12,950 | 12,950 | 12,950 |
| P/E ratio | 78.8 x | 40.4 x | 29.6 x | 31.1 x | 27.2 x | 20.7 x | 15.8 x |
| Yield | - | 0.74% | 0.97% | 0.97% | 0.64% | 0.83% | 1.09% |
| Capitalization / Revenue | - | 5.07 x | 3.58 x | 4.26 x | 4.07 x | 3.27 x | 2.93 x |
| EV / Revenue | - | 5.07 x | 3.58 x | 4.26 x | 4.07 x | 3.27 x | 2.93 x |
| EV / EBITDA | - | 29.4 x | 23.7 x | 24.6 x | 18.8 x | 15.3 x | 11.7 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | 8.01 x | 5.37 x | 6.07 x | 5.96 x | 4.7 x | 3.85 x |
| Nbr of stocks (in thousands) | 3,28,552 | 3,28,552 | 3,42,936 | 3,45,145 | 3,45,148 | - | - |
| Reference price 2 | 19.14 | 25.10 | 24.30 | 33.23 | 37.52 | 37.52 | 37.52 |
| Announcement Date | 28/02/21 | 26/04/22 | 14/04/23 | 24/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 1,628 | 2,326 | 2,693 | 3,179 | 3,958 | 4,414 |
| EBITDA 1 | - | 280.4 | 352 | 467 | 689 | 846.8 | 1,103 |
| EBIT 1 | - | 225.8 | 291.3 | 394.4 | 544 | 711.6 | 957.8 |
| Operating Margin | - | 13.87% | 12.52% | 14.65% | 17.11% | 17.98% | 21.7% |
| Earnings before Tax (EBT) 1 | - | 226.2 | 290.2 | 402.2 | 558.6 | 724.6 | 973.9 |
| Net income 1 | 80.28 | 204.2 | 269.7 | 368.3 | 507.4 | 662.4 | 887.2 |
| Net margin | - | 12.55% | 11.59% | 13.68% | 15.96% | 16.73% | 20.1% |
| EPS 2 | 0.2429 | 0.6214 | 0.8200 | 1.070 | 1.380 | 1.810 | 2.380 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | 0.1864 | 0.2360 | 0.3210 | 0.2400 | 0.3100 | 0.4100 |
| Announcement Date | 28/02/21 | 26/04/22 | 14/04/23 | 24/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 20.9% | 18.6% | 21.2% | 21.5% | 22.6% | 24.4% |
| ROA (Net income/ Total Assets) | - | 14.2% | 13.3% | - | 17.8% | 16.9% | 20.4% |
| Assets 1 | - | 1,438 | 2,022 | - | 2,848 | 3,925 | 4,357 |
| Book Value Per Share 2 | - | 3.140 | 4.530 | 5.470 | 6.300 | 7.990 | 9.750 |
| Cash Flow per Share 2 | - | 0.5800 | 0.7800 | 1.250 | 1.720 | 1.670 | 2.540 |
| Capex 1 | - | 126 | 413 | 427 | 56 | 52.5 | - |
| Capex / Sales | - | 7.72% | 17.77% | 15.85% | 1.76% | 1.33% | - |
| Announcement Date | 28/02/21 | 26/04/22 | 14/04/23 | 24/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
37.52
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +12.91% | 182.71Cr | |
| +29.98% | 68TCr | |
| +30.34% | 57TCr | |
| -3.52% | 36TCr | |
| +18.59% | 33TCr | |
| +4.07% | 28TCr | |
| +16.21% | 24TCr | |
| +9.66% | 21TCr | |
| -6.83% | 20TCr | |
| +7.09% | 17TCr |
- Stock Market
- Equities
- 300705 Stock
- Financials Hunan Jiudian Pharmaceutical Co., Ltd.